News

BioVersys Reports Results From Phase 2a ENABLE Study

NASDAQ

(RTTNews) - BioVersys AG (BIOV.SW) announced results from the Phase 2a ENABLE study of alpibectir in combination with ethionamide or AlpE in patients with newly diagnosed drug-sensitive pulmonary tuberculosis. The phase 2a ENABLE study showed early bactericidal activity in all re

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.